Conducting collaborative research locally, nationally and globally.

Skip to end of metadata
Go to start of metadata

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 36 Next »

Bakouni, H., Sharafi, H., Bahremand, A., Drouin, S., Ziegler, D., Bach, P., Le Foll, B., Schütz, C.G., Tardelli, V., Ezard, N., Siefried, K. & Jutras-Aswad, D. 2023. Bupropion for Treatment of Amphetamine-Type Stimulant Use Disorder: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials. Drug and Alcohol Dependence, 253:111018.

Best, L.M., Hendershot, C.S., Buckman, J.F., Jagasar, S., McPhee, M.D., Muzumdar, N., Tyndale, R.F., Houle, S., Logan, R., Sanches, M., Kish, S.J., Le Foll, B. & Boileau, I. 2023. Association between Fatty Acid Amide Hydrolase and Alcohol Response Phenotypes: A Positron Emission Tomography Imaging Study with [(11)C]Curb in Heavy-Drinking Youth. Biol Psychiatry, 94(5):405-415.

Bourgault, Z., Matheson, J. & Le Foll, B. 2023. Genetic Variation and Acute Responses to Cannabis. In: Martin, C.R., Patel, V.B. & Preedy, V.R. (eds.). Cannabis Use, Neurobiology, Psychology, and Treatment: Academic Press.

Boachie, N., Gaudette, E., Bazinet, R.P., Lin, L., Tyndale, R.F., Mansouri, E., Huestis, M.A., Tong, J., Le Foll, B., Kish, S.J., George, T.P. & Boileau, I. 2023. Circulating Endocannabinoids and N-Acylethanolamines in Individuals with Cannabis Use Disorder-Preliminary Findings. Brain Sci, 13(10).

Butler, K., Le Foll, B. & Di Ciano, P. 2023. The Role of Dopamine D3 Receptors in Tobacco Use Disorder: A Synthesis of the Preclinical and Clinical Literature. Curr Top Behav Neurosci, 60:203-28.

Bastien, G., McAnulty, C., Ledjiar, O., Socias, M.E., Le Foll, B., Lim, R., Hassan, A.N., Brissette, S., Marsan, S., Talbot, A., Jutras-Aswad, D. & Optima Research Group within the Canadian Research Initiative in Substance Misuse 2023. Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial. Can J Psychiatry, 68(8):572-585.

Crepeault, H., Ti, L., Jutras-Aswad, D., Wood, E., Le Foll, B., Lim, R., Bach, P., Brar, R. & Socias, M.E. 2023. Correlates of Nonfatal Overdose among Treatment-Seeking Individuals with Non-Heroin Opioid Use Disorder: Findings from a Pragmatic, Pan-Canadian, Randomized Control Trial. Journal of Substance Use and Addiction Treatment, 155:209158.

Di Ciano, P., Brands, B., Fares, A., Wright, M., Stoduto, G., Byrne, P., McGrath, M., Hasan, O.S.M., Le Foll, B. & Wickens, C.M. 2023. The Utility of THC Cutoff Levels in Blood and Saliva for Detection of Impaired Driving. Cannabis Cannabinoid Res, 8(3):408-413.

Elkrief, L., Bastien, G., McAnulty, C., Bakouni, H., Hébert, F.-O., Socias, M.E., Le Foll, B., Lim, R., Ledjiar, O., Marsan, S., Brissette, S., Jutras-Aswad, D., Bornemisza, S., Bouman, H., Elliott, S., Evans, L., Ghosh, M., Gursky, L., Vezina, L., Wild, C., Yu, A., Ahamad, K., Bach, P., Brar, R., Fairbairn, N., Fairgrieve, C., Habibian, S., Klaire, S., MacDonald, S., McLean, M., Nolan, S.C., Prinsloo, G., Sutherland, C., Wood, E., Bozinoff, N., Fischer, B., Franklin, M., Hassan, A., Kahana, D., Lagzdins, D., Marsh, D., Rehm, J., Barbeau, D., Bruneau, J., Maynard, S., Talbot, A. & Juteau, L.-C. 2023. Differential Effect of Cannabis Use on Opioid Agonist Treatment Outcomes: Exploratory Analyses from the Optima Study. Journal of Substance Use and Addiction Treatment, 149:209031.

Enns, B., Krebs, E., Whitehurst, D.G.T., Jutras-Aswad, D., Le Foll, B., Socias, M.E., Nosyk, B. & Optima Research Group within the Canadian Research Initiative in Substance Misuse 2023. Cost-Effectiveness of Flexible Take-Home Buprenorphine-Naloxone Versus Methadone for Treatment of Prescription-Type Opioid Use Disorder. Drug Alcohol Depend, 247:109893.

Elsaid, S., Truong, P., Sailasuta, N. & Le Foll, B. 2023. Evaluating Back-to-Back and Day-to-Day Reproducibility of Cortical Gaba+ Measurements Using Proton Magnetic Resonance Spectroscopy ((1)H Mrs). Int J Mol Sci, 24(9).

Gewandter, J.S., Edwards, R.R., Hill, K.P., Wasan, A.D., Hooker, J.E., Lape, E.C., Besharat, S., Cowan, P., Le Foll, B., Ditre, J.W. & Freeman, R. 2023. Cannabinoid Therapy: Attitudes and Experiences of People with Chronic Pain. Clin J Pain, 39(6):249-258.

Hassan, A.N., Agabani, Z., Ahmed, F., Shapiro, B. & Le Foll, B. 2023. The Impact of Religiosity/Spirituality on Slowing the Progression of Substance Use: Based on the National Epidemiological Survey of Alcohol and Related Conditions (Nesarc-Iii). Int J Soc Psychiatry, 69(6):1399-1408.

Hassan, A.N., Bozinoff, N., Jutras-Aswad, D., Socias, M.E., Stewart, S.H., Lim, R., Le Foll, B. & Optima Research Group 2023. Patient Satisfaction with Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results from a Pragmatic Randomized Controlled Clinical Trial. J Addict Med, 17(1):e49-e56.

Hauck, T.S., Ladha, K.S., Le Foll, B., Wijeysundera, D.N. & Kurdyak, P. 2023. Postoperative Buprenorphine Continuation in Stabilized Buprenorphine Patients: A Population Cohort Study. Addiction, 118(10):1953-1964.

Ibrahim, C., Tang, V.M., Blumberger, D.M., Malik, S., Tyndale, R.F., Trevizol, A.P., Barr, M.S., Daskalakis, Z.J., Zangen, A. & Le Foll, B. 2023. Efficacy of Insula Deep Repetitive Transcranial Magnetic Stimulation Combined with Varenicline for Smoking Cessation: A Randomized, Double-Blind, Sham Controlled Trial. Brain Stimul, 16(5):1501-1509.

Kim, S., Rajack, N., Mondoux, S.E., Tardelli, V.S., Kolla, N.J. & Le Foll, B. 2023. The Covid-19 Impact and Characterization on Substance Use-Related Emergency Department Visits for Adolescents and Young Adults in Canada: Practical Implications. J Eval Clin Pract, 29(3):447-458.

Magarbeh, L., Gorbovskaya, I., Wells, R., Jhirad, R., Le Foll, B. & Muller, D.J. 2023. Pharmacogenetics of Lethal Opioid Overdose: Review of Current Evidence and Preliminary Results from a Pilot Study. J Pers Med, 13(6).

Matheson, J. & Le Foll, B. 2023. Acute and Chronic Impact of Cannabis on Human Cognition. In: Martin, C.R., Patel, V.B. & Preedy, V.R. (eds.). Cannabis Use, Neurobiology, Psychology, and Treatment: Academic Press.

Matheson, J. & Le Foll, B. 2023. Impacts of Recreational Cannabis Legalization on Use and Harms: A Narrative Review of Sex/Gender Differences. Front Psychiatry, 14:1127660.

Mocanu, V., Bozinoff, N., Wood, E., Jutras-Aswad, D., Le Foll, B., Lim, R., Cheol Choi, J., Yin Mok, W., Eugenia Socias, M. & Optima Research Group within the Canadian Research Initiative in Substance Misuse 2023. Opioid Agonist Therapy Switching among Individuals with Prescription-Type Opioid Use Disorder: Secondary Analysis of a Pragmatic Randomized Trial. Drug Alcohol Depend, 248:109932.

Ragheb, H., Ahmad, S., Uddin, S., Le Foll, B. & Hassan, A.N. 2023. The Prevalence and Treatment Utilization of Substance Use Disorders among Muslims in the United States: A National Epidemiological Survey. Am J Addict, 32(5):497-505.

Russell, C., Law, J., Imtiaz, S., Rehm, J., Le Foll, B. & Ali, F. 2023. The Impact of Methamphetamine Use on Medications for Opioid Use Disorder (Moud) Treatment Retention: A Scoping Review. Addict Sci Clin Pract, 18(1):48.

Sokoloff, P. & Le Foll, B. 2023. A Historical Perspective on the Dopamine D3 Receptor. In: Boileau, I. & Collo, G. (eds.). Therapeutic Applications of Dopamine D3 Receptor Function: New Insight after 30 Years of Research. Cham: Springer International Publishing.

Tang, V.M., Goud, R., Zawertailo, L., Selby, P., Coroiu, A., Sloan, M.E., Chenoweth, M.J., Buchman, D., Ibrahim, C., Blumberger, D.M. & Le Foll, B. 2023. Repetitive Transcranial Magnetic Stimulation for Smoking Cessation: Next Steps for Translation and Implementation into Clinical Practice. Psychiatry Res, 326:115340.

Tang, V.M., Ibrahim, C., Rodak, T., Goud, R., Blumberger, D.M., Voineskos, D. & Le Foll, B. 2023. Managing Substance Use in Patients Receiving Therapeutic Repetitive Transcranial Magnetic Stimulation: A Scoping Review. Neuroscience & Biobehavioral Reviews, 155:105477.

Tang, V.M., Yu, D., Weissman, C.R., Jones, B.D.M., Wang, G., Sloan, M.E., Blumberger, D.M., Daskalakis, Z.J., Le Foll, B. & Voineskos, D. 2023. Treatment Outcomes in Major Depressive Disorder in Patients with Comorbid Alcohol Use Disorder: A Star*D Analysis. J Affect Disord, 339:691-697.

Tardelli, V.S., Johnstone, S., Xu, B., Kim, S., H, K.K., Gratzer, D., George, T.P., Le Foll, B. & Castle, D.J. 2023. Marked Increase in Amphetamine-Related Emergency Department Visits and Inpatient Admissions in Toronto, Canada, 2014-2021. Can J Psychiatry, 68(4):249-256.

Trick, L., Butler, K., Bourgault, Z., Vandervoort, J. & Le Foll, B. 2023. Implementation and Preliminary Evaluation of a 12-Week Cognitive Behavioural and Motivational Enhancement Group Therapy for Cannabis Use Disorder. Substance Abuse: Research and Treatment, 17:11782218231205840.

Wang, R., Trigo, J.M. & Le Foll, B. 2023. Effects of Sub-Chronic Nabiximols on Biological Markers of Individuals Undergoing a Clinical Trial for the Treatment of Cannabis Use Disorder. Am J Transl Res, 15(8):5228-5238.

Whitehurst, D.G.T., Mah, C., Krebs, E., Enns, B., Socias, M.E., Jutras-Aswad, D., Le Foll, B., Nosyk, B. & Optima Research Group within the Canadian Research Initiative in Substance Misuse 2023. Sensitivity to Change of Generic Preference-Based Instruments (Eq-5d-3l, Eq-5d-5l, and Hui3) in the Context of Treatment for People with Prescription-Type Opioid Use Disorder in Canada. Qual Life Res, 32(8):2209-2221.

Wright, M., Matheson, J., Watson, T.M., Sproule, B., Le Foll, B. & Brands, B. 2023. Gender Influences on Cannabis Use among Treatment-Seeking Adults: A Qualitative Study. Drugs: Education, Prevention and Policy:1-13.

Xiao, K.B., Grennell, E., Ngoy, A., George, T.P., Le Foll, B., Hendershot, C.S. & Sloan, M.E. 2023. Cannabis Self-Administration in the Human Laboratory: A Scoping Review of Ad Libitum Studies. Psychopharmacology (Berl), 240(7):1393–1415.

Zhang, H., Gilbert, E., Hussain, S., Veldhuizen, S., Le Foll, B., Selby, P. & Zawertailo, L. 2023. Effectiveness of Bupropion and Varenicline for Smokers with Baseline Depressive Symptoms. Nicotine Tob Res, 25(5):937-944.

  • No labels